HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Spark Therapeutics, Inc. focuses on the development of gene therapy products. The Company provides therapy products to transform the lives of patients and re-imagine the treatment of debilitating diseases.
| Q1 2020 | All Institutions | Hedge Funds 1 |
|---|---|---|
| No data found for this quarter. | ||
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
| Spark Therapeutics Inc Chart by YCharts | |
| Yahoo! Finance | finviz |
| SEC Web Site | SEC DEF 14A Filings |
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
25,500 | 2020-07-29 | 1 | |
|
MILANO VINCENT PRESIDENT & CEO |
|
0 | 2020-07-21 | 1 |
|
|
0 | 2020-07-13 | 1 | |
|
0 | 2020-07-01 | 0 | |
|
0 | 2020-06-30 | 1 | |
|
24,604 | 2020-06-29 | 1 | |
|
0 | 2020-06-12 | 1 | |
|
0 | 2020-06-11 | 1 | |
|
0 | 2020-05-21 | 1 | |
|
0 | 2020-02-03 | 0 | |
|
FAGA DANIEL EVP, CHIEF OPERATING OFFICER |
|
0 | 2020-01-06 | 1 |
|
0 | 2019-12-17 | 1 | |
|
MARRAZZO JEFFREY D CHIEF EXECUTIVE OFFICER |
|
0 | 2019-12-17 | 1 |
|
LA BARGE JOSEPH CHIEF LEGAL OFFICER |
|
0 | 2019-12-17 | 1 |
|
DALTON LISA CHIEF HUMAN RESOURCE OFFICER |
|
0 | 2019-12-17 | 1 |
|
MINGOZZI FEDERICO CHIEF SCIENTIFIC OFFICER |
|
0 | 2019-12-17 | 1 |
|
29,746,673 | 2019-12-17 | 1 | |
|
LA BARGE JOSEPH CHIEF LEGAL OFFICER LA BARGE JOSEPH CHIEF LEGAL OFFICER |
|
21,882 | 2019-03-19 | 1 |
|
VIVALDI COELHO ROGERIO EVP, CHIEF GLOBAL THERAPEUTICS |
|
No longer subject to file | 2018-03-08 | 0 |
|
0 | 2017-05-31 | 0 | |
|
SOFINNOVA VENTURE PARTNERS VIII, L.P. |
|
0 | 2015-01-29 | 0 |
| Reporting Owners | Transaction Date | Transaction Code | Shares | Share Price | Acquired or Disposed | Shares Owned Following Transaction | Combined shares owned after filing | Direct/Indirect Ownership | 10b-5 |
|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | |||||||||
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
